BAYZF - Bayer posts Q4 earnings beat; guides for higher earnings sales in 2022
Bayer (OTCPK:BAYRY -0.2%) reported Q4 net profit of €1.16B ($1.3B), up from €308M in the year-earlier quarter and beating analyst expectations of €731M, while guiding for increased earnings and sales in 2022. Q4 EBITDA came in roughly flat compared to a year ago at €2.4B, edging €2.32B consensus estimate, while revenues rose 11% Y/Y to €11.12B from €10B in Q4 2020, beating consensus expectations of €10.47B. Bayer said sales in its agricultural crop science division rose 11% Y/Y to €4.69B, with growth spread across all regions, while sales of prescription medicines increased 7.4%, with some of the division's businesses showing recovery from COVID-19 headwinds. The company said it expects the price of glyphosate, the active ingredient in its Roundup weedkiller, to come down in H2 after surging by ~250% according to some retailers' estimates due to shortages from supply chain issues and weather-related production delays last year. For FY 2022, Bayer
For further details see:
Bayer posts Q4 earnings beat; guides for higher earnings, sales in 2022